
Navigating considerations for ADCs: Guidance for the industry
This paid-for advertorial from Eurofins appeared in DDW Volume 26 – Issue 4, Fall 2025 Antibody-drug conjugates (ADCs) are increasingly promising due to advances in biologics and chemistry. With 16 FDA-approved ADCs, clinical interest is growing, though development remains complex, requiring thorough evaluation of the antibody, linker, payload, and… Read More













